In a groundbreaking advancement in the realm of chemical biology, researchers have unveiled the potent molecular glue CLEO4-88, which orchestrates the interaction between the CTLH E3 ubiquitin ligase subunit GID4 and the peroxisomal enzyme ACAA1. This discovery, published in Nature Chemical Biology, illustrates the nuanced mechanistic pathways by which small molecules can enforce protein-protein interactions, not by typical degradation but rather by functional inhibition—a novel dimension in molecular glue technology.
Molecular glues have historically been hailed for their role in targeted protein degradation (TPD), whereby they facilitate recruitment of an E3 ligase to a target protein, tagging it for ubiquitination and subsequent proteasomal destruction. This mode of action has revolutionized drug development, particularly in tackling previously ‘undruggable’ targets. However, the work led by Chana and colleagues diverges from this paradigm, demonstrating that molecular glues can exert therapeutic advantages through alternative mechanisms.
The team focused on the CTLH E3 ligase complex and homed in on GID4, a subunit within the complex known for recognizing specific degron sequences in substrates. By searching for small molecules capable of binding GID4, the researchers identified CLEO4-88, a compound with remarkable affinity, achieving a half-maximal effective concentration (EC50) of just 12.5 nM. This low nanomolar potency underscores the potential of CLEO4-88 as a molecular catalyst of protein interactions.
What makes CLEO4-88 strikingly unique is its allosteric mode of action. High-resolution atomic structural analysis reveals that the molecule does not directly interface with ACAA1 but instead binds exclusively to GID4. This binding induces a conformational shift within GID4’s architecture, effectively reshaping its interaction surface to foster binding with ACAA1. The study’s crystallographic data magnificently captures this induced-fit mechanism, illuminating an elegant route by which small molecules can modulate protein landscapes.
While the formation of a ternary complex—comprising CLEO4-88, GID4, and ACAA1—was expected to trigger ubiquitination and degradation of ACAA1, biochemical assays uncovered an unexpected twist. Despite robust complex formation, ACAA1 was not recruited to the CTLH holoenzyme for ubiquitination. Instead, the interaction inhibited ACAA1’s enzymatic thiolase activity. This phenomenon challenges prior assumptions equating molecular glue activity exclusively with targeted protein degradation and hints at a broader functional spectrum.
ACAA1, a peroxisomal thiolase, plays a pivotal role in fatty acid β-oxidation, a metabolic pathway critical for cellular energy homeostasis and lipid metabolism. Inhibition of ACAA1’s catalytic function could therefore have profound physiological implications, possibly influencing metabolic flux within peroxisomes. The data presented suggest that molecular glues like CLEO4-88 might serve as finely tuned modulators of enzymatic activity, rather than merely clearance agents, opening fresh vistas for therapeutic intervention.
Cell-based studies further corroborated the in vitro findings, with CLEO4-88 treatment promoting interaction between endogenous GID4 and ACAA1 in living cells. This in cellulo validation hints at physiological relevance, positioning CLEO4-88 not only as a valuable chemical probe but also as a potential lead compound for metabolic disorder treatments where peroxisomal enzyme modulation is advantageous.
The discovery aligns with an emerging concept in chemical proteomics: the exploitation of allostery to mediate or disrupt protein interactions through small molecules. Historically, drug discovery has prioritized orthosteric binding sites, often limiting therapeutic reach. Molecular glues extend this by exploiting transient or cryptic binding pockets that unveil upon ligand engagement, triggering structural transitions that propagate functional outcomes.
This study’s elucidation of GID4’s structural responsiveness to CLEO4-88 also underlines the versatility embedded within E3 ligase complexes. Although GID4 did not funnel ACAA1 towards degradation, its binding adaptability showcased how multiprotein assemblies can mediate diverse biological outcomes through subtle conformational fine-tuning, dependent on small-molecule effectors.
From a drug discovery perspective, the implications are profound. The ability to chemically stabilize non-native protein interactions and simultaneously inhibit enzymatic activity expands the repertoire of molecular glue utility beyond proteasome-targeted degradation. This may reduce potential drawbacks of complete protein elimination, such as compensatory mechanisms or toxicity arising from total protein loss.
Importantly, the researchers deployed a variety of complementary approaches, integrating biochemical assays, structural biology, and cellular experiments to comprehensively dissect the emerging paradigm of molecular glue functionality. This multifaceted methodology strengthens confidence in the mechanistic insights and sets a benchmark for future studies exploring the nuanced roles of small-molecule-induced protein interactions.
The broader scientific community will undoubtedly be intrigued by the concept that molecular glues can exert effects by stabilizing interactions that modify functional outputs without necessitating ubiquitin-dependent destruction. This versatility could lead to the development of innovative therapeutic agents for diseases where modulation of enzyme activity—not degradation—is the desired outcome.
Moreover, this work may inspire investigations into other E3 ligase components and their potential to engage molecular glues for unconventional regulatory outcomes. It prompts a reevaluation of ubiquitin ligase systems not just as degradation machines but as adaptable platforms amenable to precise molecular editing of cellular proteomes and enzymatic activities.
The discovery of CLEO4-88 also opens avenues for future medicinal chemistry optimization. The core scaffold could be refined to enhance specificity, cell permeability, or pharmacokinetic profiles, paving the way for translational efforts aiming to harness molecular glues to address metabolic and possibly other biochemical disorders.
Collectively, this study exemplifies the power of structural-informed molecular design combined with cellular validation to unlock new molecular mechanisms. CLEO4-88 serves as a beacon for the next generation of molecular glues, hinting at therapeutic strategies where modulation of protein function through induced interaction supplants the paradigm of target elimination.
As molecular glue research evolves, the delineation of allosteric sites and their conformational dynamics will be paramount. The discovery of CLEO4-88’s unique properties fuels enthusiasm for exploring similar compounds that can toggle the functional landscapes of proteins via induced binding, potentially transforming chemical biology, drug discovery, and therapeutic development.
This work not only enriches our understanding of the CTLH ligase system and GID4’s role but also expands conceptual frameworks regarding how small molecules can harness and repurpose endogenous protein machinery for precise, modulatory outcomes.
In conclusion, the identification and characterization of the molecular glue CLEO4-88 redefine the boundaries of small-molecule-induced protein interactions. By enabling selective inhibition of ACAA1 thiolase activity without prompting its degradation, this advance opens a new frontier for molecular glues as versatile modulators of protein function, setting the stage for innovation at the intersection of chemistry, biology, and medicine.
Subject of Research: Molecular glues mediating protein–protein interactions, targeting E3 ubiquitin ligase subunit GID4 and peroxisomal thiolase ACAA1.
Article Title: The molecular glue CLEO4-88 inhibits the ACAA1 thiolase by induced binding to GID4.
Article References:
Chana, C.K., Ben Makhlouf, I., Kim, J. et al. The molecular glue CLEO4-88 inhibits the ACAA1 thiolase by induced binding to GID4. Nat Chem Biol (2026). https://doi.org/10.1038/s41589-026-02183-4
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41589-026-02183-4
Tags: ACAA1 functional inhibitionchemical biology drug discoveryCTLH E3 ubiquitin ligaseGID4 subunit targetingmolecular glue CLEO4-88molecular glue drug developmentnon-degradative molecular glue mechanismnovel therapeutic molecular glueperoxisomal enzyme regulationprotein-protein interaction stabilizationsmall molecule protein interactiontargeted protein modulation
